SCHEMBL24976392

SCHEMBL24976392

COc1ccc(CN2[C@H]3CC[C@@H]2[C@H](NC(=O)C2CCCN(C(=O)OC(C)(C)C)CC2)C3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 3/20 0.49
ALDH1A1 P00352 3/20 0.46
EPHX2 P34913 2/20 0.45
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.41
KDM1A O60341 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24977220 0.82 L3MBTL1 (0.53) ALDH1A1MEN1KMT2AKDM1AL3MBTL1
SCHEMBL24976021 0.82 L3MBTL1 (0.53) ALDH1A1MEN1KMT2AKDM1AL3MBTL1
SCHEMBL24975769 0.82 L3MBTL1 (0.53) ALDH1A1MEN1KMT2AKDM1AL3MBTL1
SCHEMBL24976393 0.81 ALDH1A1 (0.51) ALDH1A1EPHX2LMNAL3MBTL1SMN1; SMN2
SCHEMBL29950234 0.77 ALDH1A1 (0.47) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL24977312 0.77 ALDH1A1 (0.47) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL27022355 0.73 ALDH1A1 (0.71) STSALDH1A1EPHX2LMNAMEN1
SCHEMBL24976091 0.71 L3MBTL1 (0.42) ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL31003008 0.71 ALDH1A1 (0.48) STSALDH1A1LMNAKMT2ATP53
SCHEMBL2710950 0.70 PTPN2 (0.79) STSALDH1A1EPHX2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof AMGEN INC. (US) 2023-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572374-B2 N-cyano-7-azanorbornane derivatives and uses thereof CYP3A7, CYP51A1, NT5C3B STS 743/4885ALDH1A1 793/4885EPHX2 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.